intranasal delivery is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-27. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
常规纯度与身份确认依赖反相高效液相色谱，并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成，肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同，因此各实验室报告的纯度数值不宜直接横向比较。
== Deficiencies and toxicity == An inadequate amount of a nutrient is a deficiency. Deficiencies can be due to several causes, including an inadequacy in nutrient intake, called a dietary deficiency, or any of several conditions that interfere with the utilization of a nutrient within an organism. Some of the conditions that can interfere with nutrient utilization include problems with nutrient absorption, substances that cause a greater-than-normal need for a nutrient, conditions that cause nutrient destruction, and conditions that cause greater nutrient excretion. Nutrient toxicity occurs when excess consumption of a nutrient does harm to an organism. In the United States and Canada, recommended dietary intake levels of essential nutrients are based on the minimum level that "will maintain a defined level of nutriture in an individual", a definition somewhat different from that used by the World Health Organization and Food and Agriculture Organization of a "basal requirement to indicate the level of intake needed to prevent pathologically relevant and clinically detectable signs of a dietary inadequacy". In setting human nutrient guidelines, government organizations do not necessarily agree on amounts needed to avoid deficiency or maximum amounts to avoid the risk of toxicity. For example, for vitamin C, recommended intakes range from 40 mg/day in India to 155 mg/day for the European Union. The table below shows U.S.
Using psychedelics poses certain risks of re-experiencing of the drug's effects, including flashbacks and hallucinogen persisting perception disorder (HPPD). Hallucinogen persisting perception disorder is a non-psychotic disorder that includes persistent visual changes. It is most often found among frequent users of psychedelic drugs.
There are several steps in the brewing process, which may include malting, mashing, lautering, boiling, fermenting, conditioning, filtering, and packaging. The brewing equipment needed to make beer has grown more sophisticated over time, and now covers most aspects of the brewing process. Malting is the process where barley grain is made ready for brewing. Malting is broken down into three steps in order to help to release the starches in the barley. First, during steeping, the grain is added to a vat with water and allowed to soak for approximately 40 hours. During germination, the grain is spread out on the floor of the germination room for around 5 days. The final part of malting is kilning when the malt goes through a very high temperature drying in a kiln; with gradual temperature increase over several hours. When kilning is complete, the grains are now termed malt, and they will be milled or crushed to break apart the kernels and expose the endosperm, which contains the majority of the carbohydrates and sugars; this makes it easier to extract the sugars during mashing. Mashing converts the starches released during the malting stage into sugars that can be fermented. The milled grain is mixed with hot water in a large vessel known as a mash tun. In this vessel, the grain and water are mixed together to create a cereal mash. During the mash, naturally occurring enzymes present in the malt convert the starches (long chain carbohydrates) in the grain into smaller molecules or simple sugars (mono-, di-, and tri-saccharides).
Harrison (1912–1998), American chemist who studied the structure of organic compounds and their interaction with light, first woman President of the American Chemical Society Odd Hassel (1897–1981), Norwegian chemist who established the three-dimensionality of molecular geometry, 1969 Nobel Prize in chemistry Charles Hatchett (1765–1847), English chemist who discovered niobium Herbert A. Hauptman (1917–2011), American mathematician who developed a method that opened a new era in research in determination of molecular structures of crystallized materials, 1985 Nobel Prize in chemistry Walter Hawkins (1911–1992), American chemist, a pioneer of polymer chemistry, who co-invented a polymer with antioxidants that prevented deterioration even in extreme temperatures Walter Haworth (1883–1950), British chemist, 1937 Nobel Prize in chemistry "for his investigations on carbohydrates and vitamin C" Sam Hay (PhD 2004), New Zealand chemist known for in silico enzymology, quantum mechanics roles in biological processes Alma Levant Hayden (1927–1967), American spectrophotometrist known for showing that Krebiozen was a quack anti-cancer agent Jabir Ibn Hayyan (722–804), Persian-Arab chemist and alchemist, purported author of many works in Arabic
== Target == Do6a primarily targets Pickpocket/Balboa (Ppk/Bba or Ppk1/Ppk26) ion channels that are evenly distributed on the dendrites of class IV dendritic arborizing (cIV da) neurons in the peripheral nervous system of fruit fly larvae. cIV da neurons are responsible specifically for nociception from mechanical stimuli and heat, unlike cI, cII cIII that respond to other sensory input, like proprioception or gentle touch. These neurons have highly complex dendritic trees and blocking their synaptic output significantly reduces behavioral nociceptive responses (e.g. rolling) in larvae. Do6a appears to target exclusively insect nociceptors, likely due to the parasitic reproduction cycle of the species requiring good protection against other insects. Other peptides in the venom (e.g. Do10a and Do13a) affect pain receptors in mammals. Expression of both Ppk and Bba forming a heteromeric channel complex in cIV da neurons are necessary for nociception from Do6a. Ppk/Bba belong to Degenerin/Epithelial (DEG/ENaC) protein family and respond specifically to mechanical nociception and not noxious heat. Gating of these channels is still not entirely understood. While their activation upon harsh mechanical pressure may suggest a mechanosensitive nature of these channels, peptides like Do6a and Vulnusin have been shown to activate Ppk1/Ppk26 without a presence of a mechanical stimulus, pointing towards ligand-gating instead.
Sources: en.wikipedia.org
==== New generation hydroxamate-based inhibitors ==== The pioneering hydroxamate-based inhibitors were followed by a set of 'new generation' molecules with features including a substituted aryl, a sulfonamide and a hydroxamate zinc-binding group.
== Overview == During her time as both governor and prisoner, Joan is known for creating major conflicts within Wentworth prison. The second season follows her attempting to gain control over the prison by replacing Franky with Bea in the top dog position. She also turns Will Jackson and Matthew Fletcher against each other in revenge for a past incident with Will. The third season shows a more psychotic side of Joan as Bea and the inmates turn against her and her vendetta against Will Jackson leads her to being arrested in the last episode. Joan returns to Wentworth as a prisoner in Season 4 and attempts to exonerate herself and end Bea Smith's rule, doing this first by befriending Kaz Proctor and convincing her to murder her star witness, Nils Jesper. When this fails, Joan uses her knowledge of Officer Jake Stewart's actions within the prison to have him kill Nils Jesper. As she walks free, Bea Smith ambushes her in revenge for Joan's attempted murder of Bea's girlfriend, Allie, and thrusts a screwdriver into herself, incriminating Joan for Bea's murder. Season 5 follows Joan being imprisoned for Bea's murder, as she attempts to bring down Vera Bennett by becoming Top Dog. Allie Novak attempts multiple times to get her revenge on Joan, finally succeeding by having her buried alive by Will Jackson. Throughout the sixth season, Joan appears as a hallucination to Will, taunting him and having him second guess if he succeeded in burying her alive. Will, accompanied by Vera and Jake, goes to undig her grave for closure and if there's a slim chance Joan could have escaped.
Formation of the Quinonoid Intermediate PLP acts as an 'electron sink' absorbing delocalized electron density during the reaction intermediates (countering the excess electron density on the deprotonated a-carbon). PLP facilitates the enzyme activity, increasing the acidity of the alpha carbon by stabilizing the conjugate base. The PLP-stabilized carbanion intermediate formed is the quinonoid intermediate. Tyrosine and PLP stabilized 3C-Ring formation PLP and Tyrosine stabilize negative charges during deprotonation. Tyrosine attacks the sulfur bound carbon, allowing S(CH3)(Ado) to leave, and during ring formation, Tyrosine leaves. Note inhibitors AVG and AMA bind PLP to form a ketimine and oxime respectively (whose reverse reactions are much less favorable) and prevent the ACC synthase catalyzed reaction with SAM.
The functional form of single-stranded RNA molecules, just like proteins, frequently requires a specific spatial tertiary structure. The scaffold for this structure is provided by secondary structural elements that are hydrogen bonds within the molecule. This leads to several recognizable "domains" of secondary structure like hairpin loops, bulges, and internal loops. In order to create, i.e., design, RNA for any given secondary structure, two or three bases would not be enough, but four bases are enough. This is likely why nature has "chosen" a four base alphabet: fewer than four would not allow the creation of all structures, while more than four bases are not necessary to do so. Since RNA is charged, metal ions such as Mg2+ are needed to stabilise many secondary and tertiary structures. The naturally occurring enantiomer of RNA is D-RNA composed of D-ribonucleotides. All chirality centers are located in the D-ribose. By the use of L-ribose or rather L-ribonucleotides, L-RNA can be synthesized. L-RNA is much more stable against degradation by RNase. Like other structured biopolymers such as proteins, one can define topology of a folded RNA molecule. This is often done based on arrangement of intra-chain contacts within a folded RNA, termed as circuit topology.
Sources: en.wikipedia.org
=== Long-term effects === Regular use of large amounts of kava may cause mood swings, apathy, dry, scaly skin, malnutrition, weight loss, increased susceptibility to infections, and shortness of breath. Long-term use has also been associated with liver damage; however, the available evidence remains inconclusive. The risk is higher with alcoholic or acetonic extracts, or concentrated forms like pills. Water-based kava extracts in moderate doses are considered safer, but should not be consumed with alcohol, particularly in those with a history of liver issues.
=== Bleeding === Bleeding is a known side effect of apixaban. The likelihood of bleeding increases when it is combined with other medications that affect blood clotting, such as anticoagulants, aspirin, antiplatelet medications, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and nonsteroidal anti-inflammatory drugs (NSAIDs). Large clinical trials, including the ARISTOTLE trial, have shown that these combinations can modestly raise the risk of major bleeding. In clinical practice, healthcare providers carefully assess each patient's individual risk to ensure apixaban is used safely and effectively. In some cases, patients may also report fatigue or tiredness, which can occur as a secondary effect related to anemia or blood loss rather than a direct pharmacological action of apixaban. Andexanet alfa is a US Food and Drug Administration (FDA) approved antidote for apixaban in people with uncontrolled and life-threatening bleeding events. Andexanet alfa was voluntarily withdrawn from the U.S. market effective December 22, 2025.
=== Privacy and independence === A Nature editorial suggests medical care could become dependent on AI models that could be taken down at any time, are difficult to evaluate, and may threaten patient privacy. Its authors propose that health-care institutions, academic researchers, clinicians, patients and technology companies worldwide should collaborate to build open-source models for health care of which the underlying code and base models are easily accessible and can be fine-tuned freely with own data sets.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.